Abstract
Introduction For decades it has been known that gliomas follow a non-random spatial distribution, appearing more often in some brain regions (e.g. the insula) than others (e.g. the occipital lobe). A better understanding of the localization patterns of glioma could lend clues to the origins of these types of brain tumors. Following hypotheses derived from prior research into neuropsychiatric disease and cancer, gliomas may be expected to localize to functional hub regions of the brain, regions populated by stem-like cells, and regions enriched with transcription of genetic determinants of glioma.
Methods A tumor frequency map was derived using MRI data from 335 adult patients with high- and low-grade glioma accessed from the Brain Tumor Segmentation Challenge (BraTS). First, the connectomic correlates of this map were explored by comparing distributions of tumor frequency across canonical subnetworks and regions of high functional connectivity and centrality. Second, glioma frequency across brain regions known to contain sources of neural stem cells (i.e. the hippocampus and the caudate) was compared to glioma frequency across random sets of parcels. Post-mortem microarray data from the Allen Human Brain Atlas (AHBA) was used to estimate oligodendrocyte precursor cell distribution across the brain, and the spatial correspondence of this measure with tumor frequency was tested. Third, AHBA data was also used for a partial least squares (PLS) regression analysis relating spatial transcription patterns of 20647 genes to glioma distribution. The resulting ranked lists of genes related to glioma distribution were tested for enrichment of an a priori set of genes thought to drive gliomagenesis. Finally, we constructed a multiple linear regression model combining all of the significant factors across the study into one model predicting glioma distribution.
Results Glioma frequency was elevated in association cortex and positively correlated with measures of functional hubness. Regions of the brain populated with stem-like cells, such as neural stem cells and oligodendrocyte precursor cells, exhibited a high glioma frequency. PLS regression relating gene expression patterns to glioma frequency determined two components (PLS1 and PLS2) that respectively explained 19% and 18% of the variance in glioma distribution. PLS1 was enriched with genes most strongly associated with chromatin organization, whereas PLS2 was related to synaptic signaling along with a broad set of metabolic processes. Interestingly, PLS1 was enriched with an a priori set of glioma proto-oncogenes. A multiple linear regression model incorporating the topological, cellular, and genetic contributions to tumor frequency was able to explain 58% of the variance in glioma distribution about the brain and revealed that each of these factors were independent predictors of tumor frequency.
Conclusion Glioma distribution can in part be explained by functional hubness, distributions of stem-like cells, and transcription patterns of genetic determinants of glioma. These results add to previous literature reporting the vulnerability of hub regions to neurological disease and provide support for cancer stem cell theories of glioma. Our findings illustrate how factors of diverse scale, from genetic to connectomic, can independently influence the anatomic localization of oncogenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.S.M. was funded by a Gates Cambridge Scholarship. R.R.G. was funded by a Guarantors of Brain fellowship. Data were stored and processed on the High Performance Hub for Clinical Informatics (HPHI) platform, funded by a Medical Research Council (MRC) infrastructure award (MR/M009041/1).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This work made use of publicly-accessible datasets from the Brain Tumor Segmentation Challenge, UK BioBank, and Allen Institute for Brain Science
http://braintumorsegmentation.org/